Practical insights into the role of ruxolitinib (JAKAVI®) in patients with myelofibrosis are continuing to accumulate, including data from a phase 3b expanded-access trial1 and a recent report identifying predictors of response.2 In this in-depth feature we explore the latest evidence, and speak to some key experts about its use in clinical practice. Myelofibrosis prognosis ...
Ruxolitinib in myelofibrosis: Evidence and experience
15 Nov 2019
Sponsored by Novartis Pharmaceuticals Australia Pty Ltd